Omeros (NASDAQ:OMER) Shares Gap Down - What's Next?

Omeros logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Omeros shares fell sharply, opening at $14.59 after closing at $16.68 and later trading at $13.62.
  • Quarterly results were mixed: EPS of $0.06 beat estimates, but revenue of $35.93 million missed expectations of $37.28 million; reports also cited a wider quarterly loss.
  • Analyst sentiment remains positive, with a consensus “Moderate Buy” rating and average price target of $30.33; HC Wainwright reaffirmed its Buy rating and $33 target.
  • Five stocks to consider instead of Omeros.

Omeros Corporation (NASDAQ:OMER - Get Free Report)'s stock price gapped down prior to trading on Tuesday. The stock had previously closed at $16.68, but opened at $14.59. Omeros shares last traded at $13.62, with a volume of 778,506 shares trading hands.

Top Omeros Stories

Here are a few of the latest stories about OMER:

  • Positive Sentiment: HC Wainwright reaffirmed its “buy” rating and set a $33 price target, signaling substantial upside in the analyst’s view. HC Wainwright rating
  • Neutral Sentiment: Omeros expects $5 million to $6 million of fourth-quarter income from discontinued operations, while continuing efforts to scale YARTEMLEA use. Q4 outlook
  • Negative Sentiment: Third-quarter revenue was $35.9 million, below analysts’ roughly $37.3 million estimate. Although non-GAAP EPS of $0.06 topped forecasts, reports highlighted a wider quarterly loss, weighing on sentiment. Omeros shares down on wider third-quarter loss

Analyst Ratings Changes

A number of equities analysts recently issued reports on the company. Wall Street Zen raised Omeros from a "hold" rating to a "buy" rating in a report on Saturday, August 15th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $22.00 target price on shares of Omeros in a research note on Wednesday, October 14th. HC Wainwright reissued a "buy" rating and issued a $33.00 target price on shares of Omeros in a report on Tuesday. Finally, Weiss Ratings upgraded Omeros from a "hold (c-)" rating to a "hold (c)" rating in a research note on Thursday, October 8th. Three research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $30.33.

View Our Latest Stock Report on Omeros

Omeros Stock Performance

The company has a 50-day simple moving average of $18.22 and a 200-day simple moving average of $13.76. The company has a market cap of $977.63 million, a price-to-earnings ratio of 10.56 and a beta of 2.96.

Omeros (NASDAQ:OMER - Get Free Report) last posted its quarterly earnings results on Monday, November 16th. The biopharmaceutical company reported $0.06 earnings per share for the quarter, beating analysts' consensus estimates of $0.02 by $0.04. The business had revenue of $35.93 million during the quarter, compared to analysts' expectations of $37.28 million. As a group, equities research analysts forecast that Omeros Corporation will post -0.37 EPS for the current year.

Insiders Place Their Bets

In other Omeros news, CAO David Borges sold 10,000 shares of the business's stock in a transaction on Wednesday, September 23rd. The shares were sold at an average price of $20.95, for a total transaction of $209,500.00. Following the sale, the chief accounting officer directly owned 5,000 shares in the company, valued at approximately $104,750. The trade was a 66.67% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Peter Cancelmo sold 25,000 shares of the company's stock in a transaction on Monday, August 31st. The stock was sold at an average price of $18.54, for a total transaction of $463,500.00. Following the transaction, the vice president directly owned 200 shares in the company, valued at approximately $3,708. This trade represents a 99.21% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 100,906 shares of company stock worth $1,904,955 in the last ninety days. 10.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in OMER. Sterling Capital Management LLC lifted its position in shares of Omeros by 75.3% during the 3rd quarter. Sterling Capital Management LLC now owns 1,764 shares of the biopharmaceutical company's stock valued at $34,000 after acquiring an additional 758 shares during the period. GK Wealth Management LLC acquired a new stake in shares of Omeros in the 3rd quarter worth approximately $65,000. Assetmark Inc. acquired a new stake in shares of Omeros in the 1st quarter worth approximately $38,000. Mirae Asset Global Investments Co. Ltd. purchased a new position in Omeros in the 3rd quarter valued at approximately $70,000. Finally, Parallel Advisors LLC increased its stake in Omeros by 778.1% in the 3rd quarter. Parallel Advisors LLC now owns 6,586 shares of the biopharmaceutical company's stock valued at $125,000 after purchasing an additional 5,836 shares in the last quarter. 48.79% of the stock is owned by hedge funds and other institutional investors.

About Omeros

(Get Free Report)

Omeros Corporation NASDAQ: OMER is a biopharmaceutical company focused on discovering, developing and commercializing therapies for disorders involving the complement, immune and coagulation systems. The company has also developed a pipeline of investigational therapies aimed at treating serious diseases involving complement activation and immune-system dysfunction. The company is headquartered in Seattle, Washington, and was founded in 1994. Its leading investigational programs have included narsoplimab, which targets the lectin pathway of the complement system, and OMS906, an antibody designed to inhibit MASP-3 and regulate the alternative pathway.

Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Omeros Right Now?

Before you consider Omeros, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Omeros wasn't on the list.

While Omeros currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines